Wetzel Investment Advisors’s Pacira BioSciences PCRX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q3
Sell
-100
Closed -$2.92K 674
2024
Q2
$2.92K Hold
100
﹤0.01% 687
2024
Q1
$2.61K Hold
100
﹤0.01% 795
2023
Q4
$3K Buy
+100
New +$2.93K ﹤0.01% 797

Other funds holding PCRX

Wetzel Investment Advisors's PCRX Position: Q3 2024 in Review

Wetzel Investment Advisors sold out of Pacira BioSciences (PCRX) in Q3 2024, closing a stake of 100 shares — an estimated $2.92K sold.

Wetzel Investment Advisors first reported a position in PCRX in Q4 2023 and held it in 3 quarters. The position peaked at $3K in Q4 2023. 239 funds tracked by Wall St. Rank hold PCRX as of Q3 2024.

  • Wetzel Investment Advisors reported no remaining Pacira BioSciences position as of Q3 2024 after selling out during the quarter.
  • Wetzel Investment Advisors sold 100 Pacira BioSciences shares in Q3 2024, an estimated $2.92K.
  • Wetzel Investment Advisors first reported a position in Pacira BioSciences in Q4 2023 and held it in 3 quarters.
  • Wetzel Investment Advisors's Pacira BioSciences position peaked at $3K in Q4 2023.
  • 239 funds tracked by Wall St. Rank held Pacira BioSciences as of Q3 2024.

Based on Wetzel Investment Advisors's 13F filing for Q3 2024, filed 29 Oct 2024.